

**Early Clinical Stage  
Company**


**IP Licensed from Wistar**

**Located in Philadelphia**

**Supported through \$9M  
non-dilutive capital and VC  
Pre-Seed funds**

**Co-Founders  
Michael Seiden  
Dario Altieri**





There have been many attempts at small molecule HSP90 inhibitors for cancer therapy.

**None of the HSP90 inhibitors so far have the ability to accumulate in mitochondria.**

**Ours does.**


The unique bioenergetic demands of cancer create a therapeutic opportunity to target a nodal point in cancer mitochondria.




## Lead Asset-Gamitrinib

GA Mitochondrial Matrix Inhibitor

**A first in class inhibitor of TRAP1, a HSP90 Chaperone, in mitochondria.**



## Subcellular Localization of 17-AAG vs Gamitrinib







## Trial at Fox Chase Cancer Center



A Phase I trial is underway at Fox Chase Cancer Center under the leadership of Tony Olszanski. To date, **clinical activity has been seen in 2 of 10 patients with dosing still well below the MTD.**

Currently at Dose Level 4 with no serious adverse events including one patient currently on drug for 6 months.



# 2023-2024 Seed Supported Activities

- Complete an Expanded Phase I Trial with PK and PD
- Design and Prepare for Launch of a Phase II Trial in a Rare Disease
- Optimize Sourcing, Synthesis & Manufacture of Gamitrinib
- Continue to Build and Strengthen the Gladius Team

**Ask**

**Raising 10M Seed Round**

**Summer / Fall 2023**